FDA’s Expansive Power to Search Facilities Reaffirmed with Limits

A Pennsylvania court has reaffirmed the legality of an old, rarely used Food and Drug Administration (FDA) power: the “inspection warrant.”

The court said in its April 17 ruling that the FDA has the authority to get a court-ordered warrant to search your facilities and your computers without demonstrating probable cause that a crime has been committed—a much lower, easier standard for the agency than the evidence needed in criminal cases.

Interestingly, though, the court ruled that if the FDA were to legally force its way into your facilities and/or computers using this sort of warrant, you don’t have to answer any questions—not even divulge passwords.

While FDA calls this power an “inspection warrant,” the court, in affirming that FDA has the right to use it, called it an “administrative search warrant.”

FDA went to court for the inspection warrant when a company called Spa & Organic Essentials refused to cooperate after the FDA found anecdotal evidence that a 2018 nationwide outbreak of salmonella was traceable back to lots of a controversial regulated food product, kratom, which it sold.

“On March 16, 2018, FDA’s Coordinated Outbreak and Evaluation Network issued an assignment requesting an inspection and sample collection at Spa & Organic Essentials as part of this investigation into this nationwide outbreak…approximately 199 people from 41 states were infected…At least 50 people were hospitalized,” the court decision said.

“Armed with this information, between March and May 2018 the FDA sought on five separate occasions to secure the cooperation of the owners” to do a food safety inspection. “The owner or Spa & Organic Essentials refused to cooperate by providing any details regarding the destruction and distribution of the kratom, or disclose the name of his supplier,” saying he believed the FDA was “trying to destroy his livelihood.”

The FDA secured the warrant on September 27 and executed it on October 3.

Then, the company filed a motion to quash the search warrant and any evidence gathered by it. The court ordered FDA to give the company its evidence of probable cause that an inspection was warranted (not that a crime had been committed—a big distinction).

The FDA responded with a motion seeking both enforcement and to hold the company in contempt for refusing to provide computer passwords or make any other statements to the FDA.

“Thus, on the basis of the owner’s failure to do something that was not explicitly called for under the search warrant, namely make statements and provide passwords, the FDA sought a further enforcement order and a contempt citation,” the court decision says.

The court ruled against both the motion to quash and FDA’s attempt to make the owner talk and cite him for contempt.

In other words, if the FDA gets a court order to inspect, it has the right to do so.

“However, the case also is a reminder of a key limitation on FDA’s inspectional authority, namely the absence of any statutory authority to compel any company employee to speak about any topic during an FDA inspection. Thus, regulated industry must remember that allowing its employees to speak during an FDA inspection is a purely voluntary decision, and not one that FDA has any statutory authority to compel under the FDC Act,” says attorney Anne K. Walsh of the law firm Hyman Phelps, & McNamara, PC in a May 3 blog.

The case is: In the Matter of Administrative Establishment Inspection of: Spa & Organic Essentials of Pennsylvania, No. 1:18-MC-546, 2019 U.S. Dist. LEXIS 65476 (M.D. Pa. Apr. 17, 2019).

Kratom poses interaction dangers with pain prescriptions

According to the National Institute on Drug Abuse (NIDA), kratom acts like an opioid and it interacts with opioids—but it’s not designated as a drug, and it’s not currently illegal.

Those facts can make it potentially dangerous in situations in which opioids are prescribed for pain. It’s also known by the names biak, ketum, kakuam, ithang, and thom.

Two of its chemical ingredients induce sedation and decrease pain, especially when users consume large amounts, NIDA says. “The FDA reports note that many of the kratom-associated deaths appeared to have resulted from adulterated products or taking kratom with other potent substances, including illicit drugs, opioids, benzodiazepines, alcohol, gabapentin, and over-the-counter medications, such as cough syrup,” NIDA says. “Two deaths were reported following exposure from kratom alone with no other reported substances.”